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Background and purpose — Metal-on-metal hip implants have 
been widely used, especially in the USA, Australia, England 
and Wales, and Finland. We assessed risk of death and updated 
data on the risk of cancer related to metal-on-metal hip replace-
ments. 
Patients and methods — A cohort of 10,728 metal-on-metal 
hip replacement patients and a reference cohort of 18,235 con-
ventional total hip replacement patients were extracted from 
the Finnish Arthroplasty Register for the years 2001–2010. Data 
on incident cancer cases and causes of death until 2011 were 
obtained from the Finnish Cancer Registry and Statistics Fin-
land. The relative risk of cancer and death were expressed as 
standardized incidence ratio (SIR) and standardized mortality 
ratio (SMR). SIR/SIR ratios and SMR/SMR ratios, and Poisson 
regression were used to compare the cancer risk and the risk of 
death between cohorts. 
 Results — The overall risk of cancer in the metal-on-metal 
cohort was not higher than that in the non-metal-on-metal cohort 
(RR = 0.91, 95% CI: 0.82–1.02). The risk of soft-tissue sarcoma 
and basalioma in the metal-on-metal cohort was higher than in 
the non-metal-on-metal cohort (SIR/SIR ratio = 2.6, CI: 1.02–6.4 
for soft-tissue sarcoma; SIR/SIR ratio = 1.3, CI: 1.1–1.5 for basali-
oma). The overall risk of death in the metal-on-metal cohort was 
less than that in the non-metal-on-metal cohort (RR = 0.78, CI: 
0.69–0.88). 
Interpretation — The overall risk of cancer or risk of death 
because of cancer is not increased after metal-on-metal hip 
replacement. The well-patient effect and selection bias contrib-
ute substantially to the findings concerning mortality. Arthro-
cobaltism does not increase mortality in patients with metal-on-
metal hip implants in the short term. However, metal-on-metal 
hip implants should not be considered safe until data with longer 
follow-up time are available.

Metal-on-metal hip implants have been widely used, espe-
cially in the USA, Australia, England and Wales, and Fin-
land (AOANJRR 2010, NJR 2011, Cohen 2012, Seppänen 
et al. 2012). The theoretical health risks related to chroni-
cally elevated blood metal ion concentrations induced 
by abnormal wear and corrosion of the metal-on-metal 
implants—apart from local symptoms around the failing 
implant—include systemic symptoms of poisoning (Steens 
et al. 2006, Oldenburg et al. 2009, Rizzetti et al. 2009, 
Tower 2010, 2012, Mao et al. 2011, Sotos and Tower 2013, 
Zyviel et al. 2013) and carcinogenesis (Mäkelä et al. 2012, 
Smith et al. 2012, Brewster et al. 2013). Systemic metal 
ion toxicity cases due to a failed hip replacement are rare. 
However, there have been several recent reports of systemic 
cobalt toxicity following revision of fractured ceramic 
components, and also in patients with a failed metal-on-
metal hip replacement (Steens et al. 2006, Oldenburg et al. 
2009, Rizzetti et al. 2009, Tower 2010, 2012, Mao et al. 
2011, Sotos and Tower 2013, Zyviel et al. 2013). Possible 
clinical findings include fatigue, weakness, hypothyroid-
ism, cardiomyopathy, polycythemia, visual and hearing 
impairment, cognitive dysfunction, and neuropathy. Fatal 
cardiomyopathy due to systemic cobalt toxicity after hip 
replacement has been reported (Zyviel et al. 2013). 
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Metal debris from hip replacement may be associated with 
chromosomal aberrations and DNA damage (Case et al. 1996, 
Bonassi et al. 2000, Daley et al. 2004). However, the risk of 
cancer is not increased after conventional metal-on-polyeth-
ylene total hip replacement or after first-generation metal-on-
metal total hip arthroplasty (Visuri et al. 1996, 2010a). The 
short-term overall cancer risk after modern metal-on-metal 
hip arthroplasty is not increased either (Mäkelä et al. 2012, 
Smith et al. 2012, Brewster et al. 2013). However, recent link-
age studies of overall cancer risk are based on hospital episode 
statistics, which may have less quality assurance than cancer 
registry data (Smith et al. 2012, Brewster et al. 2013). Annual 
updating of cancer registry data concerning the metal-on-
metal issue is advisable.
In this paper, we update our earlier published results on risk 
of cancer (Mäkelä et al. 2012) and give an assessment of the 
overall and cause-specific mortality in primary metal-on-metal 
and non-metal-on-metal hip replacement patients who were 
operated on from 2001 to 2010, by combining data from the 
Finnish Arthroplasty Register, the Population Register Centre, 
and the Finnish Cancer Registry. The reason for this early 
updating of the cancer data was to be able to detect a cancero-
genic effect of metal-on-metal implants as early as possible.
Patients and methods
The metal-on-metal cohort consisted of 10,728 patients and 
the non-metal-on-metal cohort consisted of 18,235 patients 
(Mäkelä et al. 2012). For details, see Mäkelä et al. (2012). 
None of the subjects were lost to follow-up.
Follow-up and statistical analysis
The patients were followed up from the date of the first hip 
replacement until death, or until December 31, 2011. The data 
from the Finnish Arthroplasty Register were linked with the 
data from the Finnish Cancer Registry (Teppo et al. 1994) 
using the unique personal identity codes of the patients. Dates 
of death or emigration and causes of death were obtained from 
Statistics Finland. The Finnish Cancer Registry covers more 
than 99% of all cancer cases in Finland (Teppo et al. 1994). 
Determination of the cause of death is based on the medical or 
forensic evidence, which provides the grounds for issue of a 
death certificate. Forensic determination of the cause of death 
may be necessary if the death is not the result of an illness, 
if it is accidental or violent, or if it is caused by a treatment 
procedure or an occupational disease. In most other cases, the 
death certificate is based on medical evidence (Statistics Fin-
land 1999).
The numbers of observed cases for each cancer category 
and for each cause of death category and person-years at fol-
low-up were stratified by sex, calendar period (2001–2005 and 
2006–2011), 5-year age group, and follow-up time since the 
operation (< 5 years and ≥ 5 years). The expected number of 
cancer and the number of patients expected to die from each 
cause were calculated by applying the number of person-
years in each stratum to the corresponding cancer incidence 
rate and mortality rate, respectively, in the Finnish popula-
tion. The relative risk of cancer or death was expressed as the 
ratio of the observed and expected number of cases, i.e. stan-
dardized incidence ratio (SIR) or standardized mortality ratio 
(SMR). Risk ratio of the 2 SIRs (SIR/SIR ratio) was used for 
comparison of the metal-on-metal cohort and the non-metal-
on-metal cohort. The 95% confidence intervals (CIs) were 
defined assuming that the number of observed cases followed 
a Poisson distribution. A Poisson regression analysis to further 
compare the cancer risk in the metal-on-metal and non-metal-
on-metal cohorts was performed for all cancers and for colon 
cancer, prostate cancer, lung cancer, and basalioma. These 
cancer types were included in the regression analysis because 
the number of cases was sufficient. A Poisson regression 
model was also used for comparison of the risk of death in the 
metal-on-metal cohort and in the non-metal-on-metal cohort. 
In Poisson regression analyses, age was stratified in 30-year 
categories and follow-up time was stratified in 3 categories 
(for cancer: < 2, 2–5, and > 5 years since the operation; and for 
death: < 1, 1–5, and > 5 years since the operation). In addition, 
sex was added in the model.
Results
The metal-on-metal cohort gave 48,978 person-years and the 
non-metal-on-metal cohort gave 108,904 person-years (Table 
1). The mean follow-up of the metal-on-metal cohort was 4.6 
(1–11) years and that of the non-metal-on-metal cohort was 
6.0 (1–11) years.
Cancer incidence
The overall cancer risk in the metal-on-metal cohort was not 
higher than that in the Finnish population (Table 2). In the 
regression model, the overall cancer risk in the metal-on-metal 
cohort was not any higher than that in the non-metal-on-metal 
cohort (RR = 0.9, CI: 0.8–1.0; p = 0.1). 
Risk of basalioma in the metal-on-metal cohort was higher 
than in the Finnish population (SIR = 1.4, CI: 1.2–1.6; 
p < 0.001) (Table 2). Risk of basalioma in the metal-on-metal 
cohort was also higher than in the non-metal-on-metal cohort, 
both in the non-stratified analysis (SIR/SIR ratio = 1.3, CI: 
1.1–1.5) (Table 3) and in the stratified regression analysis 
(RR = 1.3, CI: 1.1–1.5; p = 0.01). 
The SIR of skin melanoma in the metal-on-metal cohort was 
1.1 (CI: 0.67–1.7) and that in the non-metal-on-metal cohort 
was 1.3 (CI: 1.0–1.7) relative to the Finnish population (Table 
2). Risk of melanoma in the metal-on-metal cohort was not 
any higher than in the non-metal-on-metal cohort, both in the 
non-stratified regression analysis (Table 3) and in the stratified 
regression analysis (RR = 0.8, CI: 0.5–1.4; p = 0.4). 
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7 soft-tissue sarcomas were found in the metal-on-metal 
cohort during the follow-up period (SIR = 2.1, CI: 0.9–4.4) 
(Table 2). The risk of soft-tissue sarcoma in the metal-on-
metal cohort was higher than in the non-metal-on-metal cohort 
(RR = 2.6, CI: 1.0–6.4) (Table 3). 2 new soft-tissue sarcomas 
were diagnosed in 2011 in the metal-on-metal cohort, after the 
closing year (2010) of the earlier analysis of the same cohort 
(Mäkelä et al. 2012). A 66-year-old male patient with a Biomet 
ReCap-Magnum THA inserted in both hips in 2005 was oper-
ated for a retroperitoneal low-grade liposarcoma fixed to the 
right ileopsoas muscle (8 kg in weight and 30 cm in diameter). 
A 64-year-old male patient with an ASR resurfacing inserted 
in his left hip in 2004 was operated for a low-grade liposar-
coma of the left adductor lodge in 2011. 
In the regression analysis, the risks of lung cancer (RR = 
0.9, CI: 0.7–1.3; p = 0.7), prostate carcinoma (RR = 1.1, CI: 
0.9–1.4; p = 0.4), and colon carcinoma (RR = 1.0, CI: 0.6–1.7; 
p = 1.0) were not significantly different in the metal-on-metal 
cohort and the non-metal-on-metal cohort. 
Mortality
The all-cause SMR was 0.65 (CI: 0.58–0.71) for the metal-
on-metal cohort and 0.72 (CI: 0.70–0.75) for the non-metal-
on-metal cohort, as compared to the Finnish population (Table 
4). The overall risk of death in the metal-on-metal cohort was 
less than that in the non-metal-on-metal cohort (RR = 0.78, 
CI: 0.69–0.88; p < 0.001). SMRs for deaths are presented in 
the Figure. SMR was statistically significantly less than in the 
Table 1. Number of patients (n) according to age at operation, and number of person-years according to the age 
at follow-up. The non-metal-on-metal cohort consisted of implants with metal-on-polyethylene, ceramic-on-
polyethylene, and ceramic-on-ceramic bearing surfaces
  Metal-on-metal (MoM) cohort Non-metal-on-metal cohort
 Men Women Men Women
Age n Person-years  n Person-years  n  Person-years  n  Person-years 
< 20 6 14 3 16 – – – –
20–29 25 101 16 56 4 17 7 23
30–39 158 435 67 236 30 101 20 87
40–49 741 2,833 468 1,569 143 616 157 491
50–59 2,275 8,516 1,642 6,226 850 3,327 922 3,711
60–69 2,257 11,955 1,581 8,383 2,260 11,140 2,739 12,557
70–79 762 4,599 594 3,263 3,044 19,193 5,394 29,603
≥ 80 65 430 48 346 697 7,844 1,953 20,193
Total 6,289 28,884 4,419 20,094 7,028 42,239 11,192 66,665
Table 2. Observed numbers of cancer cases, the expected numbers of cancer cases approximated from the Finnish popu-
lation, and standardized incidence ratios with 95% confidence intervals—according to site—are given for the metal-on-
metal cohort and for the non-metal-on-metal cohort. The latter cohort consisted of implants with metal-on-polyethylene, 
ceramic-on-polyethylene, and ceramic-on-ceramic bearing surfaces 
 MoM cohort Non-MoM cohort
Primary site Obs Exp SMR 95% CI Obs Exp SMR 95% CI
All sites 497 534 0.93 0.85–1.01 1952 1908 1.02 0.98–1.06
Stomach 13 12 1.08 0.57–1.84 57 53 1.07 0.81–1.39
Colon 20 29 0.69 0.42–1.05 118 132 0.89 0.74–1.06
Lung 32 53 0.61 0.41–0.85 b 126 181 0.70 0.58–0.82 c
Corpus uteri 14 13 1.08 0.59–1.81 61 58 1.05 0.80–1.35
Prostate 135 124 1.09 0.91–1.27 334 334 1.00 0.90–1.10
Kidney 16 18 0.91 0.52–1.47 62 61 1.01 0.77–1.29
Bladder 11 18 0.61 0.30–1.08 80 71 1.12 0.89–1.39
Soft-tissue sarcoma 7 3 2.14 0.86–4.40 11 12 0.95 0.47–1.69
Non-Hodgkin lymphoma 17 21 0.82 0.48–1.31 81 73 1.11 0.88–1.38
Hodgkin lymphoma 1 1 0.79 0.02–4.40 1 3 0.35 0.01–1.92
Multiple myeloma 5 6 0.79 0.26–1.83 28 28 1.02 0.68–1.47
Leukemia 7 9 0.75 0.30–1.55 38 38 1.00 0.71–1.37
Melanoma 21 19 1.09 0.67–1.65 73 56 1.30 1.02–1.63 a
Basalioma 178 132 1.35 1.16–1.55 c 626 586 1.07 0.99–1.15
Obs: observed number of cancer cases; Exp: expected number of cancer cases from the Finnish population; 
SIR: standardized incidence ratio; CI: confidence interval.
a
 p < 0.05, b p < 0.01, c p < 0.001.
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Finnish population during the first 4 postoperative follow-up 
years in the metal-on-metal cohort and during the first 7 post-
operative years in the non-metal-on-metal cohort. 
The SMR for cardiovascular deaths was 0.67 (CI: 0.56–0.78) 
in the metal-on-metal cohort and 0.74 (CI: 0.70–0.78) in the 
non-metal-on-metal cohort, relative to the Finnish population 
(Table 4). The SMR for cardiovascular deaths in a follow-up 
time of 5 years or more since operation was 0.81 (CI: 0.50–
1.2) in the metal-on-metal cohort and 0.98 (CI: 0.90–1.1) in 
the non-metal-on-metal cohort relative to that in the Finnish 
population. The separately analyzed SMR for ischemic heart 
disease deaths in a follow-up time of 5 years or more since 
operation was 0.77 (CI: 0.40–1.34) in the metal-on-metal 
cohort and 0.90 (CI: 0.80–1.01) in the non-metal-on-metal 
cohort relative to that in the Finnish population. The risk of 
cardiovascular deaths in the metal-on-metal cohort was less 
than that in the non-metal-on-metal cohort (RR = 0.79, CI: 
0.64–0.97; p = 0.02). Separately analyzed risk for ischemic 
heart disease deaths in the metal-on-metal cohort was not any 
higher than in the non-metal-on-metal cohort (RR = 0.78, CI: 
0.60–1.02; p = 0.07).
The risk of death from cancer in the metal-on-metal cohort 
was less than in the non-metal-on-metal cohort (RR = 0.78, 
CI: 0.63–0.97; p = 0.02). The risks of death from respiratory 
disease and of death from accidents and violence in the metal-
on-metal cohort were similar to those in the non-metal-on-
metal cohort (RR = 0.86, CI: 0.42–1.74; p = 0.7; and RR = 
0.92, CI: 0.61–1.39; p = 0.7, respectively).
The only statistically significant interaction in the category 
regression analysis was that for implant type and sex in deaths 
from all causes (p = 0.01). The risk ratio for male patients in 
the metal-on-metal cohort was 0.70 (CI: 0.60–0.82) and for 
female patients in this cohort it was 0.98 (CI: 0.78–1.2).
 
Table 3. SIR/SIR ratios for the metal-on-metal group and 
the non-metal-on-metal group (consisting of implants 
with metal-on-polyethylene, ceramic-on-polyethylene, 
and ceramic-on-ceramic bearing surfaces) with 95% 
confidence intervals, according to site 
Primary site SIR/SIR ratio 95% CI
All sites 0.91 0.82–1.00
Stomach 1.01 0.56–1.82
Colon 0.77 0.48–1.23
Lung 0.87 0.59–1.28
Prostate 1.09 0.89–1.33
Kidney 0.87 0.51–1.51
Bladder 0.54 0.29–1.01
Uterus 1.02 0.58–1.82
Soft tissue 2.55 1.02–6.36
Non-Hodgkin lymphoma 0.73 0.44–1.22
Hodgkin lymphoma 3.00 0.31–28.7
Multiple myeloma 0.83 0.33–2.09
Leukemia 0.78 0.35–1.71
Melanoma 0.85 0.52–1.37
Skin, basal cell carcinoma 1.26 1.07–1.49
SIR: Standardized incidence ratio. 
Table 4. Observed and expected numbers of deaths, and standardized mortality ratios for the metal-on-metal and non-
metal-on-metal cohorts in the main disease groups 
 MoM cohort Non-MoM cohort
Cause of death Obs Exp SMR 95% CI Obs Exp SMR 95% CI
Cancer 114 173 0.66 0.55–0.78 c 764 873 0.87 0.81–0.93 c
Cardiovascular 131 196 0.67 0.56–0.78 c 1,274 1,719 0.74 0.70–0.78 c
Respiratory 11 25 0.44 0.22–0.78 b 84 204 0.41 0.33–0.50 c
Accidents and violence 45 46 0.97 0.71–1.29 180 158 0.82 0.69–0.97 a
All causes 365 562 0.65 0.58–0.71 c 2,785 3,846 0.72 0.70–0.75 c
MoM: metal-on-metal; Obs: observed number of deaths; Exp: expected number of deaths; SMR: standardized mortality ratio; 
CI: confidence interval.
a
 p < 0.05, b p < 0.01, c p < 0.001.
Standardized mortality ratios (SMRs) for deaths from all diseases in 
annual follow-up of metal-on-metal (MoM) and non-metal-on-metal 
(non-MoM) cohorts.
D
ow
nl
oa
de
d 
by
 [T
am
pe
re 
Un
ive
rsi
ty]
 at
 02
:14
 23
 Ju
ne
 20
16
 
36 Acta Orthopaedica 2014; 85 (1): 32–38
Discussion
The main finding of this study was that the overall risk of 
cancer was not higher than in the non-metal-on-metal cohort. 
This finding is in accordance with previous findings (Visuri et 
al. 1996, 2010a, Onega et al. 2006, Smith et al. 2012, Mäkelä 
et al. 2012, Brewster et al. 2013). Patient selection—i.e. the 
healthy-patient effect—had an appreciable influence on over-
all and site-specific risk of death during the first years of 
follow-up, both in the metal-on-metal and in the non-metal-
on-metal cohorts. The overall and site-specific risk of death 
was not higher in the metal-on-metal cohort than in the non-
metal-on-metal cohort, not even after the patient selection 
bias had ceased after the first 5 years of follow-up. The find-
ings concerning risk of death agree with previously published 
results (Visuri et al. 1994, 2010b, Lie et al. 2000, Ramiah et 
al. 2007, McMinn et al. 2012). The risk of soft-tissue sarcoma 
and basalioma in the metal-on-metal cohort was higher than 
in the non-metal-on-metal cohort, as in our previous report 
(Mäkelä et al. 2012). 2 liposarcomas at the site of metal-on-
metal hip replacement were found in 2011 in Finland. The 
risk of soft-tissue sarcoma and basalioma may be elevated by 
chance alone. 
Strengths and limitations of the study
One strength of the present study was the population-based 
design, with high numbers of patients with metal-on-metal hip 
implant. We were able to assess mortality according to cause 
of death, and to determine the incidence of different cancer 
types by combining data from the Finnish Arthroplasty Reg-
ister and the Finnish Cancer Registry. One weakness was the 
short follow-up time. Another weakness was the lack of infor-
mation on potential confounding factors regarding mortality 
and cancer risk. Furthermore, the supposed systemic compli-
cations from metal-on-metal replacements, such as cardiomy-
opathy, are rare. The ability of registry data to pinpoint deaths 
from cardiomyopathy may be inadequate. 
Comparison with other studies
The long-term overall risk of death was not increased using 
first-generation metal-on-metal hip implants (Visuri et al. 
2010b). The 10-year life expectancy of conventional total hip 
arthroplasty patients is higher than that of the general popula-
tion (Visuri et al. 1994, Lie et al. 2000, Ramiah et al. 2007). 
Male patients with metal-on-metal Birmingham hip resurfac-
ing had a lower risk of death than those with a conventional 
hip device (McMinn et al. 2012). However, the Birmingham 
hip resurfacing patients were younger and healthier than 
those with a conventional hip replacement. These findings by 
McMinn et al. are in accordance with our data. Patient selec-
tion, i.e. the healthy-patient effect, probably explains a major 
part of the better survival of hip replacement patients com-
pared to the standard population. Cardiovascular deaths due 
to cobaltism associated with metal-on-metal hip implants are 
rare and exceptional (Zyviel et al. 2013). Most arthropros-
thetic cobaltism cases are probably curable when the implant 
has been revised, and cannot therefore be detected on the basis 
of mortality data. 
The cancer risk of the patients with first-generation metal-
on-metal total hip arthroplasty was not elevated, even in long-
term follow-up (Visuri et al. 1996). Using hospital discharge, 
cancer, and mortality records, Brewster et al. (2013) studied 
the incidence of cancer in 1,317 metal-on-metal resurfacing 
arthroplasty patients in Scotland who were operated between 
2000 and 2009. The risk of cancers overall (n = 39) was not 
increased (Brewster et al. 2013). Smith et al. (2012) studied 
40,576 hip replacement patients with metal-on-metal bearing 
surfaces and 248,995 with alternative bearings, based on data 
from the National Joint Registry of England and Wales and 
hospital episode statistics. Compared to alternative bearings, 
there was no evidence that metal-on-metal bearing surfaces 
were associated with an increased overall risk of cancer (after 
a mean follow-up of 3 years). There was no increase in the risk 
of malignant melanoma or hematological, prostate, and renal 
tract cancers either. Furthermore, the overall cancer risk in 
our metal-on-metal cohort was not increased in our previous 
report covering patients operated during the years 2001–2010 
who were followed until 2010 (Mäkelä et al. 2012). All these 
previous findings are in accordance with our current findings 
with a follow-up time until the end of 2011.
The risk of soft-tissue sarcoma in the metal-on-metal cohort 
was increased in our previous report, but not statistically sig-
nificantly (Mäkelä et al. 2012). In the linkage study based on 
data from the National Joint Registry of England and Wales 
and hospital episode statistics (Smith et al. 2012), sarcoma 
risk associated with meta-on-metal hip replacements was 
not analyzed separately. In our work, 2 new sarcoma cases 
were diagnosed in the metal-on-metal cohort in 2011 after 
the previous analysis based on follow-up data until 2010. 
To our knowledge, the 2 liposarcomas diagnosed in 2011 in 
Finland are the first descriptions of liposarcoma at the site of 
a metal-on-metal hip implant. Stephensen et al. (1999) pub-
lished a case report of a liposarcoma in the adductor lodge in a 
57-year-old male rheumatoid patient with a conventional total 
hip arthroplasty. However, the total number of sarcoma cases 
in our study was small. The increased incidence of sarcomas 
in the metal-on-metal cohort may still be a chance finding. 
Hundreds of thousands of metal-on-metal hip replacements 
have been performed worldwide, but only 5 malignant local 
tumors at the site of first-generation metal-on-metal replace-
ments have been reported previously (Visuri et al. 2006). 
A risk of melanoma has been associated with conventional 
total hip arthroplasty in some of the earlier studies (Nyren 
et al. 1995, Olsen et al. 1999, Visuri et al. 2003, 2006) but 
not all of them (Visuri et al. 2010a). Incidence of melanoma 
was found to be increased in patients with a conventional hip 
implant inserted during 2005–2009 in Scotland (SIR = 1.4, 
CI: 1.1–1.9), but not in patients with a metal-on-metal hip 
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resurfacing device (Brewster et al. 2013). The incidence of 
melanoma in the non-metal-on-metal cohort in the current 
study was higher than in the Finnish general population, as 
also found in our previous report (Mäkelä et al. 2012). Mela-
noma risk in the metal-on-metal cohort was similar to that in 
the non-metal-on-metal cohort. The increased incidence of 
melanoma in the non-metal-on-metal cohort may have been 
due to survey bias. In the study based on the National Joint 
Registry of England and Wales, the risk of melanoma was not 
higher in metal-on-metal patients than in patients with other 
bearing options in the first 7 years after arthroplasty (Smith 
et al. 2012). However, the assessment of outcome was based 
on linkage to hospital episode statistics, which may have been 
associated with less quality assurance than data from a cancer 
registry. Information on some cancers may have been missing, 
e.g. cutaneous melanoma, which does not necessarily lead to 
hospital admission (Smith et al. 2012, Brewster et al. 2013). 
The metal-on-metal cohort showed a higher risk of basali-
oma than the non-metal-on-metal cohort, which is in accor-
dance with our previous report (Mäkelä et al. 2012). Basalioma 
incidence was increased in the patients with a conventional 
hip implant inserted during 2005–2009 in Scotland (SIR = 
1.1, CI: 1.0–1.2), but not in patients with a metal-on-metal hip 
resurfacing (Brewster et al. 2013). In other previous studies on 
total hip replacement patients, basalioma was either not regis-
tered at all or was included in the category of other skin can-
cers (Visuri et al. 2006, Smith et al. 2012). In theory, levels of 
metal ions in the skin could be elevated after metal-on-metal 
hip replacement, perhaps causing DNA damage together with 
ultraviolet radiation. However, we are not aware of any studies 
that have been conducted to address this issue. 
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